SK bioscience

본문바로가기

KOR ENG

sitemap

PR

SK bioscience company news updates

Press Releases

SK bioscience Receives ‘Grade A’ Rating on ESG Evaluation from the Korea Institute of Corporate Governance & Sustainability

2022.11.25
SK bioscience Donates to International Vaccine Institute to Support Global Vaccine R&D

2022.11.17
SK bioscience Announces New Strategy for Continuous Growth

2022.11.01
SK bioscience and Hilleman Laboratories to Co-develop New Vaccine Platforms

2022.10.27
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

2022.10.25
SK bioscience Appoints New Executives towards Global Business Growth

2022.10.21
SK bioscience Submits Emergency Use Listing (EUL) of SKYCovione™ to the World Health Organization

2022.09.08
SK bioscience Begins First Shipment of Korean COVID-19 Vaccine

2022.09.02
SK-Bill & Melinda Gates Foundation met to discuss shared commitments to global health

2022.08.16
SK bioscience Announces Adolescent Authorization of Protein Based COVID-19 Vaccine, Nuvaxovid

2022.08.12
SK bioscience Submits Application for Conditional Marketing Authorization of COVID-19 Vaccine, SKYCovion™ to European Medicines Agency

2022.08.01
SK bioscience Submits Conditional Marketing Authorization Application of COVID-19 Vaccine, SKYCovion™ to the Medicines and Healthcare Products Regulatory Agency

2022.07.29